全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Value of Procollagen Type I Aminoterminal Propeptide in Women with Breast Cancer with regard to Metastases

DOI: 10.4061/2011/853484

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background. The aim of this study was to show the importance of the bone marker procollagen type 1 aminoterminal propeptide (P1NP) in detecting bone metastases in women suffering from breast cancer. We furthermore investigated to what degree P1NP is correlated to the degree of bone metastases, and if P1NP is increased in patients with metastases other than bone. Patients and Methods. We analyzed 80 serum samples of women (17 premenopausal/63 postmenopausal) with breast cancer. Therefore we used a specific immunoassay “ELECSYS 2010” by Roche Diagnostics. We divided our group of patients with regard to menopausal status, sites of metastases and number of bone metastases. Results. As a result we found higher concentrations of P1NP in women with radiologically confirmed bone metastases (median: 125.75?ng/mL) in comparison to the collective without bone involvement (median: 73.61?ng/mL). However, both groups showed values above the applied cutoff values of median 27.8?ng/mL for premenopausal women and median: 37.1?ng/mL for the postmenopausal group due to the fact that all patients had cancer. Furthermore higher P1NP concentrations were found in women with more than 5 sites of bone metastases (median: 183.9?ng/mL) than in patients with only one site of bone metastases (median: 37?ng/mL). Also patients with no bone involvement but other sites of metastases showed quite high P1NP concentrations (median: 73.61?ng/mL). Conclusion. The marker of bone turnover procollagen type 1 aminoterminal propeptide can be considered as a useful tool for estimating the extent of bone involvement and for the detection of bone metastases. P1NP cannot replace conventional methods for detecting bone metastases such as radiological methods but it can help clarify unclear radiological results. This study does not take into account the change of P1NP concentration during the course of therapy. 1. Introduction Bone mainly consists of two components. There are the cellular elements such as osteoclasts, osteoblasts, and osteocytes, and there is the cellular matrix representing the main component of bone. 90% of the cellular matrix of bone is collagen tissue; the remaining 10% are noncollagenous proteins and minerals. Especially collagen type 1 is crucial for the typical structure of bone. Synthesis of mature type 1 collagen is realised by the precursor proteins procollagen and tropocollagen. Mature type 1 collagen is a heterotrimer consisting of two identical a1 chains and one a2 chain. During collagen synthesis specific proteases remove N- and C-terminal extensions of the precursor

References

[1]  M. J. Seibel and M. E. Kraenzlin, “Osteoporose- Moderne Diagnostik. Therapeutische Konsequenzen für Klinik und Praxis,” in Interdisziplin?res Osteoporose Symposium (1. IDOS), pp. S13–S17, Basel, Schweiz, Oktober 1995.
[2]  K. Von der Mark, Structure, Biosynthesis and Gene Regulation of Collagens in Cartilage and Bone, Dynamics of Bone and Cartilage Metabolism, Academic Press, Orlando, Fla, USA, 1999.
[3]  B. Goldberg, M. B. Taubman, and A. Radin, “Procollagen peptidase: its mode of action on the native substrate,” Cell, vol. 4, no. 1, pp. 45–50, 1975.
[4]  M. Klepzig, H. Sauer-Eppel, D. Jonas, and G. M. Oremek, “Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma,” Anticancer Research, vol. 28, no. 4, pp. 2443–2446, 2008.
[5]  D. I. Rosenthal, “Radiologic diagnosis of bone metastases,” Cancer, vol. 80, supplement 8, pp. 1595–1607, 1997.
[6]  C. De la Piedra, N. A. Castro-Errecaborde, M. L. Traba et al., “Bone remodeling markers in the detection of bone metastases in prostate cancer,” Clinica Chimica Acta, vol. 331, no. 1-2, pp. 45–53, 2003.
[7]  M. A. Diaz-Martin, M. L. Traba, C. De la Piedra, R. Guerrrero, C. Mendez-Davila, and E. G. De la Pena, “Aminoterminal propetide of the type I collagen and bone alkaline phosphatase in the study of bone metastases assoziated with prostatic carcinoma,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 59, no. 2, pp. 125–132, 1999.
[8]  K. Jung, M. Lein, C. Stephan et al., “Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications,” International Journal of Cancer, vol. 111, no. 5, pp. 783–791, 2004.
[9]  M. Koizumi, Y. Yonese, I. Fukui, and E. Ogata, “The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone,” British Journal of Urology International, vol. 87, no. 4, pp. 348–351, 2001.
[10]  B. V. Jensen, J. S. Johansen, T. Skovsgaard, J. Brandt, and B. Teisner, “Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer,” International Journal of Cancer, vol. 98, no. 4, pp. 582–589, 2002.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133